Items where authors include "Hoskin, P."

Article

Simões, R. orcid.org/0000-0003-3874-3128, Gulliford, S., Seddon, B. et al. (13 more authors) (2024) Predicting radiotherapy response, toxicities and quality-of-life related functional outcomes in soft tissue sarcoma of the extremities (PredicT) using dose–volume constraints development: a study protocol. BMJ Open, 14 (8). e083617. ISSN 2044-6055

Rescigno, P., Porta, N., Finneran, L. et al. (26 more authors) (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205. 114103. ISSN 0959-8049

Zhong, J. orcid.org/0000-0001-5325-3739, Kobus, M. orcid.org/0000-0002-1290-0626, Maitre, P. et al. (9 more authors) (2023) MRI-guided Pelvic Radiation Therapy: A Primer for Radiologists. RadioGraphics, 43 (11). ARTN e230052. ISSN 0271-5333

Andratschke, N., Willmann, J., Appelt, A.L. orcid.org/0000-0003-2792-9218 et al. (16 more authors) (2022) European Society for Radio-therapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making. The Lancet Oncology, 23 (10). e469-e478. ISSN 1470-2045

Parker, C.C., James, N.D. orcid.org/0000-0002-7314-8204, Brawley, C.D. orcid.org/0000-0003-3641-278X et al. (43 more authors) (2022) Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLOS Medicine, 19 (6). e1003998. ISSN 1549-1277

Choudhury, A., Porta, N., Hall, E. et al. (9 more authors) (2021) Hypofractionated radiotherapy in locally advanced bladder cancer : an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncology, 22 (2). pp. 246-255. ISSN 1470-2045

Sartor, O., Hoskin, P., Coleman, R.E. orcid.org/0000-0002-4275-1043 et al. (6 more authors) (2016) Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate, 76 (10). pp. 905-916. ISSN 0270-4137

Burton, C., Linch, D., Hoskin, P. et al. (10 more authors) (2006) A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. British Journal of Cancer, 94 (6). pp. 806-813. ISSN 0007-0920

Burton, C., Smith, P., Vaughan-Hudson, G. et al. (5 more authors) (2005) Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. British Journal of Haematology, 130 (4). pp. 536-541. ISSN 0007-1048

Conference or Workshop Item

Swinton, M., Portner, R., Brooks, L. et al. (8 more authors) (2023) MR Delta Radiomics during Radiotherapy to Prostate Cancer: Does Dose per Fraction Matter? In: ESTRO 2023, 13-16 May 2023, Vienna, Austria.

Portner, R., McWilliam, A., Zhong, J. et al. (16 more authors) (2022) Prostate Magnetic Resonance Imaging Delta-Radiomics during Image-Guided Conventional Fractionation and Stereotactic Ablative Radiotherapy. In: UNSPECIFIED.

Proceedings Paper

Thiruthaneeswaran, N., Bibby, B.A.S., Pereira, R. et al. (8 more authors) (2020) The radiosensitivity index predicts benefit from HDR brachytherapy in high-risk prostate cancer. In: Radiotherapy & Oncology. ESTRO 2020, 28 Nov - 01 Dec 2020, Online. Elsevier , S1086-S1087.